Vinorelbine
Vinorelbine (vinorelbine) is a small molecule pharmaceutical. Vinorelbine was first approved as Navelbine on 1994-12-23. It is used to treat breast neoplasms, hodgkin disease, non-small-cell lung carcinoma, and ovarian neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vinorelbine tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NAVELBINE | Laboratoires Pierre Fabre | N-020388 DISCN | 1994-12-23 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| hodgkin disease | — | D006689 | C81 |
| non-small-cell lung carcinoma | — | D002289 | — |
| ovarian neoplasms | EFO_0003893 | D010051 | C56 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9390 | Injection, vinorelbine tartrate, 10 mg |
Clinical
Clinical Trials
533 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 29 | 113 | 36 | 3 | 15 | 180 |
| Non-small-cell lung carcinoma | D002289 | — | — | 17 | 61 | 38 | 4 | 12 | 130 |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 6 | 24 | 19 | — | 4 | 49 |
| Neoplasms | D009369 | — | C80 | 18 | 13 | 5 | — | 2 | 30 |
| Hodgkin disease | D006689 | — | C81 | 2 | 13 | 5 | — | 1 | 21 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 8 | 5 | — | 1 | 15 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 3 | 3 | 5 | — | — | 10 |
| Lymphoma | D008223 | — | C85.9 | 3 | 8 | 1 | — | — | 10 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 5 | 1 | — | — | 9 |
| Sarcoma | D012509 | — | — | 3 | 6 | 1 | — | — | 8 |
| Rhabdomyosarcoma | D012208 | — | — | 3 | 5 | 2 | — | — | 8 |
| Malignant mesothelioma | D000086002 | — | — | 1 | 3 | 3 | — | 1 | 8 |
Show 22 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 3 | 9 | — | — | — | 10 |
| Small cell lung carcinoma | D055752 | — | — | 3 | 3 | — | — | 1 | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 2 | — | — | — | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 4 | — | — | — | 4 |
| Male breast neoplasms | D018567 | — | — | 2 | 1 | — | — | — | 3 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 3 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 3 | 1 | — | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 2 | — | — | — | 3 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 2 | — | — | — | 3 |
| Mesothelioma | D008654 | — | C45 | — | 3 | — | — | — | 3 |
Show 34 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | — | — | — | — | 2 |
| Adrenocortical carcinoma | D018268 | — | — | 1 | — | — | — | — | 1 |
| Wilms tumor | D009396 | EFO_0000212 | — | 1 | — | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Vaginal neoplasms | D014625 | — | C52 | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Pheochromocytoma | D010673 | — | — | 1 | — | — | — | — | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | 1 | — | — | — | — | 1 |
| Islet cell carcinoma | D018273 | — | C25.4 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vinorelbine |
| INN | vinorelbine |
| Description | Vinorelbine is a vinca alkaloid with a norvinblastine skeleton. It has a role as an antineoplastic agent and a photosensitizing agent. It is a vinca alkaloid, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a methyl ester, an acetate ester and a ring assembly. |
| Classification | Small molecule |
| Drug class | vinca alkaloids |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2 |
Identifiers
| PDB | — |
| CAS-ID | 71486-22-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL553025 |
| ChEBI ID | 480999 |
| PubChem CID | 5311497 |
| DrugBank | DB00361 |
| UNII ID | Q6C979R91Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,440 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,468 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use